The fund, managed by Epic BioVentures, targets to invest in 3-5 healthcare companies with modest capital requirements. They work closely with portfolio companies to maximize value at exit, aiming to sell to a corporate partner within 3-5 years. With a track record of successful exits, the fund's management team is located in key medical technology innovation centers across the United States. The fund is targeted to raise $125 million and plans to close by fall 2013.